Bone and bone derived factors in kidney disease

Area of Science:

• Nephrology
• Endocrinology
• Bone Metabolism

Background:

• Mineral and bone disorder (MBD) is a common complication in chronic kidney disease (CKD).
• CKD-MBD has severe consequences, including fractures, cardiovascular events, and increased mortality.
• Current treatments for CKD-MBD are insufficient, underscoring the need for better therapeutic strategies.

Purpose of the Study:

• To review novel pathways regulating systemic factors in CKD-MBD.
• To examine the roles of anemia, inflammation, and metabolic pathways in CKD-MBD.
• To emphasize internal bone mechanisms contributing to renal osteodystrophy.

Main Methods:

• Literature review focusing on recent findings in CKD-MBD.
• Exploration of regulatory pathways for mineral and bone metabolism in CKD.
• Analysis of specific internal bone mechanisms like HNF4α, TGF-β1, and sclerostin.

Main Results:

• Anemia, inflammation, and metabolic pathways significantly influence CKD-MBD.
• Internal bone mechanisms, including HNF4α, TGF-β1, and sclerostin, are critical in renal osteodystrophy.
• Skeletal abnormalities in CKD-MBD can persist independently of systemic mineral levels.

Conclusions:

• Despite progress, effective treatments for CKD-MBD morbidity and mortality remain elusive.
• Further research into novel therapeutic targets is essential for managing CKD-MBD.
• A comprehensive approach addressing both systemic factors and intrinsic bone mechanisms is necessary.